BAYN:F-Bayer Aktiengesellschaft (EUR)

COMMON STOCK | Drug Manufacturers-General | F

Last Closing Price

EUR 51.88

Change

0.00 (0.00)%

Market Cap

EUR 50.68B

Volume

9.80K

Average Target Price

EUR 62.80 (+21.05%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, and self-care solutions in the dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. Bayer Aktiengesellschaft has a collaboration agreement with MD Anderson Cancer Center at the University of Texas to develop cancer treatments; and research collaboration agreements with Haplogen GmbH and Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases. The company distributes its products through wholesalers, pharmacies, supermarket and drugstore chains, online and other retailers, and hospitals, as well as directly to farmers. It has strategic research alliance with Kyoto University, Sensyne Health plc, and Atomwise Inc. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-03-07 )

Largest Industry Peers for Drug Manufacturers-General

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
JNJ:F Johnson & Johnson

N/A

EUR342.89B 23.70 14.83
RHO:F Roche Holding AG

N/A

EUR244.07B 19.68 11.30
RHO5:F Roche Holding AG

N/A

EUR241.94B 19.52 11.95
NOT:F Novartis AG

N/A

EUR165.76B 29.87 11.21
LLY:F Eli Lilly and Company

N/A

EUR165.72B 25.43 19.31
PFE:F Pfizer Inc

N/A

EUR160.28B 16.80 12.88
NOTA:F Novartis AG

N/A

EUR159.19B 19.74 10.80
4AB:F AbbVie Inc

N/A

EUR157.45B 32.55 17.81
6MK:F Merck & Co., Inc

N/A

EUR154.63B 21.87 13.07
BRM:F Bristol-Myers Squibb Company

N/A

EUR113.14B 94.49 29.06

ETFs Containing BAYN

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-General)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 7.06% 71% C- 51% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 7.06% 71% C- 50% F
Trailing 12 Months  
Capital Gain -19.06% 26% F 10% F
Dividend Return 4.37% 61% D- 53% F
Total Return -14.70% 20% F 10% F
Trailing 5 Years  
Capital Gain -47.06% 14% F 14% F
Dividend Return 13.88% 18% F 31% F
Total Return -33.18% 11% F 13% F
Average Annual (5 Year Horizon)  
Capital Gain -10.46% 14% F 16% F
Dividend Return 3.32% 43% F 44% F
Total Return -7.14% 11% F 14% F
Risk Return Profile  
Volatility (Standard Deviation) 22.71% 51% F 63% D
Risk Adjusted Return -31.45% 11% F 14% F
Market Capitalization 50.68B 57% F 97% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-General)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 22.68 56% F 39% F
Price/Book Ratio 1.59 83% B 60% D-
Price / Cash Flow Ratio 10.34 41% F 27% F
EV/EBITDA 8.55 66% D 49% F
Management Effectiveness  
Return on Equity -39.83% 9% F 13% F
Return on Invested Capital 3.98% 29% F 55% F
Return on Assets 3.53% 17% F 67% D+
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 1.33 6% F 32% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.